Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated a positive financial trajectory, as evidenced by an operating revenue increase of 43% year-over-year, outpacing consensus expectations. The company has also raised its gross margin guidance for 2025 to a range of 76-77%, indicating improved profitability, alongside a focus on enhancing Light Adjustable Lens (LAL) volumes through strategic engagement initiatives. Furthermore, potential catalysts for future growth include an expanding LDD installed base and better utilization rates, which could enhance overall revenue and margin performance in the coming quarters.

Bears say

The financial analysis indicates a negative outlook for RxSight due to declining utilization rates of light adjustable lenses (LALs), with monthly utilization decreasing to 8.0 LALs per light delivery device (LDD) in 3Q25 from 8.7 in 2Q25 and 10.1 in 3Q24. The company's guidance for FY2026 revenue of $120-135 million reflects a decline of 11% year-over-year, which is notably below both internal and external estimates, signaling potential struggles in meeting market expectations. Additionally, declining revenue trends, including a 14% year-over-year decrease to $30.3 million in one quarter, alongside anticipated gross margin pressure due to higher inventory costs, further compound the challenges facing the company.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.